Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Genalice is a private Dutch genomics software company that develops high-performance next-generation sequencing secondary analysis tools for researchers, clinical laboratories, and healthcare organizations. Its core offerings focus on ultra-fast read alignment, variant calling, population calling, trio analysis, somatic analysis, and copy number variation analysis for large-scale DNA data sets. The company positions its technology as a scalable software platform that reduces compute, storage, and workflow bottlenecks in clinical genomics and population-scale sequencing. Genalice's products are used in human genetics, oncology, and broader genomic analysis settings, with additional applications in agrigenomics. Rather than developing therapeutics, the company commercializes bioinformatics infrastructure intended to accelerate genomic interpretation and support diagnosis and precision medicine workflows.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Genalice.